Evidence map›Paper›PMID 33770132›Full record

ArticlePloS one2021

Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season.

Masayoshi Shinjoh, Norio Sugaya, Yoshio Yamaguchi, Ichiro Ookawara, Yuji Nakata, Atsushi Narabayashi, Munehiro Furuichi, Naoko Yoshida, Akinobu Kamei, Yuu Kuramochi and 18 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Cu-MOF-NHMikrochimica acta · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 1 country.

Masayoshi ShinjohDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Norio SugayaDepartment of Pediatrics, Keiyu Hospital, Kanagawa, Japan.ORCID 0000-0003-4198-7414
Yoshio YamaguchiInstitute of Clinical Research & Department of Infection and Allergy, National Hospital Organization Tochigi Hospital, Tochigi, Japan.
Ichiro OokawaraDepartment of Pediatrics, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Yuji NakataDepartment of Pediatrics, Nippon Koukan Hospital, Kanagawa, Japan.
Atsushi NarabayashiDepartment of Pediatrics, Kawasaki Municipal Hospital, Kanagawa, Japan.
Munehiro FuruichiDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Naoko YoshidaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Akinobu KameiDepartment Pediatrics, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Yuu KuramochiDepartment of Pediatrics, Subaru Health Insurance Society Ota Memorial Hospital, Gunma, Japan.
Akimichi ShibataDepartment of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
Motoko ShimoyamadaDepartment of Pediatrics, Saitama City Hospital, Saitama, Japan.
Hisataka NakazakiDepartment of Pediatrics, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.
Naohiko MaejimaDepartment of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Erika YuasaDepartment of Pediatrics, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
Eriko ArakiDepartment of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
Naonori MaedaDepartment of Pediatrics, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Takuma OhnishiDepartment of Pediatrics, National Hospital Organization Saitama Hospital, Saitama, Japan.
Mitsuhiro NishidaDepartment of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
Nobuhiko TaguchiDepartment of Pediatrics, Keiyu Hospital, Kanagawa, Japan.
Makoto YoshidaDepartment of Pediatrics, Sano Kosei General Hospital, Tochigi, Japan.
Kenichiro TsunematsuDepartment of Pediatrics, Hino Municipal Hospital, Tokyo, Japan.
Meiwa ShibataDepartment of Pediatrics, Yokohama Rosai Hospital, Kanagawa, Japan.
Yasuhiro HiranoDepartment of Pediatrics, Hiratsuka City Hospital, Kanagawa, Japan.
Shinichiro SekiguchiDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Chiharu KawakamiYokohama City Institute of Public Health, Yokohama, Japan.
Keiko MitamuraDepartment of Pediatrics, Eiju General Hospital, Tokyo, Japan.
Takao TakahashiDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPAshikaga Red Cross Hospital · JPkeiyu Hospital · JPNational Hospital Organization · JPEiju General Hospital · JPFuji Heavy Industries Health Insurance Society Ota Memorial Hospital · JPHiratsuka City Hospital · JPKawasaki Municipal Hospital · JPNagano Municipal Hospital · JPNippon Koei (Japan) · JPSaiseikai Utsunomiya hospital · JPSaitama Municipal Hospital · JPSapporo Kosei General Hospital · JPShizuoka City Shimizu Hospital · JPShizuoka Red Cross Hospital · JPTokyo Dental College Ichikawa General Hospital · JPTokyo Medical Center · JPTokyo Metropolitan Ohtsuka Hospital · JPYokohama Municipal Citizen's Hospital · JPYokohama Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months-15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%-46%) and 74% (95% CI, 39%-89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%-77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.

Indexed as

Diagnostic Tests, RoutineSeasonsAdolescentChildChild, PreschoolDose-Response Relationship, ImmunologicFemaleHospitalizationHumansInfantInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMaleTreatment OutcomeInfluenza Vaccines

Identifiers

PMID33770132
PMCPMC7997015
OpenAlexW3137119862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.